We will have three thematic research projects each of which integrates the complementary expertise of investigators from New York area institutions in the Center:
Statistical and graph theory models for organizing scalable data will be used to integrate genomic and epigenomic information from cellular networks and physiological measurements to enable the identification of new drug targets and new ways of using currently FDA-approved drugs, both singly and in combinations, to be used to treat diseases for which they were not originally intended, while also predicting drug toxicity
Drug repositioning for multiple forms of a target will be developed using selective inhibitors of phosphodiesterase isoforms as anti-depressant drugs while considering the genomic/epigenomic status of each phosphodiesterase.
Multiscale whole-organ physiological models for predicting drug action will be built using the immersed boundary method for the pathophysiology of a human heart model. The human models will be used to identify new drug targets for heart failure and to understand and predict therapeutic and adverse drug actions.